EHP Funds Inc’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

EHP Funds Inc’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-107,964	Closed	-$5.61K	–	167
2024 Q1	$5.61K	Hold	107,964	–	–	﹤0.01%	150
2023 Q4	$6.96K	Sell	107,964 -79,950	-43%	-$9.06K	﹤0.01%	161
2023 Q3	$41.3K	Hold	187,914	–	–	0.02%	159
2023 Q2	$22.4K	Hold	187,914	–	–	0.01%	214
2023 Q1	$9.26K	Hold	187,914	–	–	﹤0.01%	290
2022 Q4	$44K	Sell	187,914 -21,038	-10%	-$789	0.01%	213
2022 Q3	$12K	Buy	208,952 +18,100	+9%	+$1.09K	﹤0.01%	383
2022 Q2	$17K	Buy	190,852 +56,532	+42%	+$12.5K	﹤0.01%	387
2022 Q1	$48K	Buy	+134,320	New	+$59.2K	0.01%	305

Other funds holding CLDI.WS

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

EHP Funds Inc's CLDI.WS Position: Q2 2024 in Review

EHP Funds Inc sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q2 2024, closing a stake of 107,964 shares — an estimated $5.61K sold.

EHP Funds Inc first reported a position in CLDI.WS in Q1 2022 and held it in 9 quarters. The position peaked at $48K in Q1 2022. 15 funds tracked by Wall St. Rank hold CLDI.WS as of Q2 2024.

EHP Funds Inc reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q2 2024 after selling out during the quarter.
EHP Funds Inc sold 107,964 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q2 2024, an estimated $5.61K.
EHP Funds Inc first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q1 2022 and held it in 9 quarters.
EHP Funds Inc's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $48K in Q1 2022.
15 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q2 2024.

Based on EHP Funds Inc's 13F filing for Q2 2024, filed 14 Aug 2024.